Borbanya Praxis Egeszsegugyi Kft.
- Address
- lock Available on a paid plan
Cardiovascular Disease Research
At Borbanya Praxis Egeszsegugyi Kft., clinical trials in cardiovascular diseases focus on conditions such as atrial fibrillation, hypertension, atherosclerotic cardiovascular disease, and prevention of heart failure. The research is mainly aimed at improving treatment effectiveness, lowering cardiovascular risk, and testing new approaches that may reduce major heart and vessel complications.
- Atrial fibrillation and treatment-related bleeding risk
- Hypertension and blood pressure control in high-risk patients
- Atherosclerotic cardiovascular disease and prevention of cardiovascular events
- Heart failure risk reduction and long-term outcome improvement
These studies reflect a strong interest in therapies that may better protect patients with established or high-risk cardiovascular disease.
Metabolic and Weight Management Studies
The site also conducts research in nutritional and metabolic diseases, especially type 2 diabetes, obesity, overweight, and related chronic weight management needs. These trials are designed to assess whether new treatments can improve blood sugar control, support weight loss, and help patients manage metabolic risk more effectively.
- Type 2 diabetes and improved glucose control
- Obesity and body weight reduction
- Overweight and long-term weight management
- Type 2 diabetes with inadequate control on current therapy
Much of this work explores combined approaches that may offer broader benefits for people living with metabolic disease and excess weight.
Kidney and Cardiometabolic Risk Research
Several trials at this Hungarian health care facility examine the connection between chronic kidney disease, type 2 diabetes, and cardiovascular risk. The main purpose is to evaluate whether new therapies can slow kidney decline, improve related health markers, and reduce the chance of serious cardiorenal complications.
- Chronic kidney disease progression in people with diabetes
- Chronic kidney disease with hypertension
- Cardiorenal risk in patients with overweight or obesity
- Kidney protection alongside metabolic and cardiovascular care
This area of research brings together kidney disease, diabetes, and cardiovascular prevention in one clinical setting.
Lipid and Triglyceride Disorders
Another important focus is nutritional and metabolic disease research related to abnormal blood fats, including hyperlipidemia, mixed dyslipidemia, and severe hypertriglyceridemia. These trials are intended to test new ways to lower harmful lipid levels and improve long-term cardiovascular health.
- Hyperlipidemia and LDL cholesterol reduction
- Mixed dyslipidemia and broader lipid control
- Severe hypertriglyceridemia and triglyceride lowering
- High cardiovascular risk linked to abnormal blood lipids
The research supports better management of lipid disorders that can contribute to heart disease and other serious complications.
Broader Internal Medicine and Special Population Research
Some studies at Borbanya Praxis Egeszsegugyi Kft. address conditions that do not fit neatly into a single category, including broader metabolic and cardiovascular questions in specific patient groups. This work is aimed at improving everyday care, refining treatment choices, and supporting better outcomes across multiple related conditions.
- Type 2 diabetes with associated risk factors
- Congenital, hereditary, and neonatal diseases and abnormalities
- Otorhinolaryngologic diseases in selected research settings
- General clinical research where the therapeutic area is not fully specified
This mix of studies shows a versatile clinical research environment with attention to both common chronic disease and other specialized medical needs.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 24 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Novo Nordisk A/S2active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S4trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Borbanya Praxis Egeszsegugyi Kft.
lock Showing 1 of 25 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) | Amgen Inc. | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 24 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Semaglutide | 4 | Unknown | 2024-04-19 | 2026-05-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.